the cost utility of five TNF-α inhibitors (in combination with methotrexate [+MTX]) versus MTX monotherapy using …). Abstract: Results:Results: Etanercept+MTX was the most cost-effective treatment strategy in the base-case scenario up to a WTP … patients who achieved the ACR50 criteria. With the exception of infliximab, all of the TNF-α inhibitors were sensitive to drug …

-to-head. To compare the effectiveness of the biologics etanercept, infliximab, adalimumab and golimumab, the manufacturer … biologics were considered equally effective, then etanercept, adalimumab and golimumab had almost equal costs and equal QALYs … treatments in 'Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis' (NICE clinical guideline 199); and …

sensitivity analyses were conducted on all relevant parameters. Results: Adalimumab, etanercept, adalimumab plus methotrexate and … infliximab plus methotrexate had incremental cost-effectiveness ratios (ICERs) versus methotrexate monotherapy of $US63_769, $US … etanercept versus methotrexate was $US85_100 per QALY. The average lifetime cost across all treatment arms in a woman diagnosed …

, cyclosporin, glucocorticoids, etanercept and infliximab clinically and statistically significantly improved QOL in patients with … RA. Refractory RA is poorly defined but we used the definition of failing at least two DMARDs. Methotrexate, leflunomide …

(TNF) inhibitors (infliximab - 6, etanercept - 2, infliximab and etanercept - 1 and adalimumab - 1). Of the latter, no …-effectiveness ratio (ICER) for spa-exercise treatment was &U20AC;7465 (95% CI 3294, 14 686) per QALY. The ICERs for infliximab, etanercept … and adalimumab were &U20AC;5307-237 010, &U20AC;29 815-123 761 and &U20AC;7344-33 303 per QALY, respectively. Abstract …

Objective: To estimate the cost effectiveness (from the UK NHS and personal social service perspectives) of infliximab … plus methotrexate (MTX) compared with MTX alone, in the treatment of patients with severe rheumatoid arthritis (RA) who … suggested that infliximab plus MTX had an ICER of Lstg 33_618 per QALY gained. Alternative modelling assumptions and various …

- infliximab and etanercept - were registered for use by patients with RA. These drugs have shown the ability to reduce disease … was to assess the potential impact on the Danish healthcare budget of prescribing infliximab or etanercept to patients …